<DOC>
	<DOCNO>NCT00455728</DOCNO>
	<brief_summary>This study multicenter , open label , observational , post marketing surveillance study NutropinAq® Austria , France , Germany , Italy , Spain , Romania United Kingdom collect long-term safety effectiveness information NutropinAq® treatment paediatric growth disorder .</brief_summary>
	<brief_title>A Post Marketing Surveillance Program NutropinAq® Paediatric Growth Disorders</brief_title>
	<detailed_description>The objective study collect long term safety effectiveness information Ipsen 's growth hormone ( GH ) NutropinAq® regard treatment paediatric growth disorder GH indicate .</detailed_description>
	<criteria>Children either sex treat NutropinAq® treatment growth failure Patients willing comply followup appointment throughout study participation Written inform consent sign parent liable parent legal guardian applicable , child applicable Patients treat NutropinAq® Patients close epiphysis Patients active neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>